Eli Lilly recently announced its fourth-quarter 2024 earnings. The company's profit doubled, reaching $4.41 billion, driven by strong sales of its diabetes and obesity drugs, Mounjaro and Zepbound. Mounjaro's sales surged 60% to $3.53 billion, while Zepbound generated $1.9 billion in revenue. Additionally, breast cancer treatment Verzenio saw a 36% revenue increase, reaching $1.55 billion. Overall, revenue climbed 45% to $13.53 billion, with adjusted per-share earnings of $5.32, surpassing Wall Street expectations. For the full year of 2024, Mounjaro sales more than doubled to $11.54 billion, and Zepbound recorded $4.9 billion in its first year. Analysts anticipate further growth in 2025, with expected sales of over $18 billion for Mounjaro and over $10 billion for Zepbound. Eli Lilly forecasts adjusted earnings between $22.50 and $24 per share and revenue between $58 billion and $61 billion for 2025. Despite these positive results, sales of Mounjaro and Zepbound fell short of some analyst expectations. However, the company's strong 2025 forecast has reassured investors, leading to a 3.4% increase in Eli Lilly's stock price, closing at $870.37.